Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 7Recruiting 6Terminated 2Not yet recruiting 2Suspended 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × amivantamab × Clear all
NCT07586202 2026-05-14

AmiNA

Janssen Research & Development, LLC

Phase 2 Not yet recruiting
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06855849 2025-03-04

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

Yonsei University

Phase 2 Not yet recruiting
85 enrolled
Gastrointestinal

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡